Alicia M. Douglas

Hunter Medical Research Institute — Australia

Medicine · Health Sciences

9h-index412citations48works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(29), Neuroblastoma Research and Treatments(12), ATP Synthase and ATPases Research(12), Cancer, Hypoxia, and Metabolism(10), Advanced Proteomics Techniques and Applications(6)

Publications48 total

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
2025Open Access
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
2025Open Access
DDDR-38. Leveraging the immunomodulatory effects of dordaviprone (ONC201) to induce long-term survival response in diffuse midline glioma patients and models
Neuro-Oncology·2025Open Access
EXTH-83. Exploiting Cell-of-Origin Vulnerabilities to Guide Multimodal Strategies in Diffuse Midline Glioma
Neuro-Oncology·2025Open Access
EXTH-89. Precision Targeting of PI3K/mTOR in Diffuse Midline Glioma: GCT007 as a Novel Brain-Penetrant PIK3CA Inhibitor
Neuro-Oncology·2025Open Access
CSIG-13. TARGETING GENETIC DEPENDENCIES EXPOSES DIFFUSE MIDLINE GLIOMA CELL OF ORIGIN VULNERABILITIES
Neuro-Oncology·2024Open Access
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
2024Open Access
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
2024Open Access
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
2024Open Access
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
2024Open Access
Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
2024Open Access
Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling
2024Open Access
DIPG-36. DRD2 ANTAGONISM RESCUES IMMUNE-TUMOR SURVEILLANCE, WARMING THE TUMOR IMMUNE MICROENVIRONMENT OF DIFFUSE MIDLINE GLIOMA MODELS
Neuro-Oncology·2024Open Access
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Journal of Clinical Investigation·2024· 30 citedOpen Access
EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992)
Neuro-Oncology·2023Open Access
EXTH-31. EXPLOITING THE GENETIC DEPENDENCY ON PI3K/MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2023Open Access
CAR T cell therapies for diffuse midline glioma
Trends in cancer·2023· 38 citedOpen Access
Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
2023Open Access
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
2023Open Access
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Matthew D. Dun(46), Ryan J. Duchatel(45), Evangeline R. Jackson(43), Izac J. Findlay(42), Abdul Mannan(40), Zacary P. Germon(40), Dilana E. Staudt(38), Brett Nixon(38), Padraic S. Kearney(34), Holly P. McEwen(34), David A. Skerrett‐Byrne(34), Mika L. Persson(32), Nicholas A. Vitanza(31), Nathan D. Smith(30), Javad Nazarian(30), Frank Alvaro(28), Martin R. Larsen(28), Carl Koschmann(28), Tyrone S. Beitaki(27), Esther Hulleman(27)